Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Avista Doubles API Manufacturing Capacity At Colorado Facility

By Avista Pharma Solutions | November 15, 2017

Avista Pharma Solutions, Inc. has completed facility upgrades that effectively double the company’s API manufacturing capacity at its Longmont, Colorado site.

During the expansion, the site’s three existing GMP drug substance manufacturing suites were upgraded, and a fourth GMP suite was added. The facility’s non-GMP capacity was also doubled with the addition of two largescale development suites.

Among the new equipment installations were four walk-in hoods, three 50-gallon glass-lined reactors, three Hastelloy agitated filter dryers, and various small-scale reactors and mixing vessels. The new equipment will provide additional scale and enable processing of complex and potent categories of chemical compounds.

Safety and containment controls were also upgraded during the expansion, giving Avista Pharma the ability to manufacture materials rated up to occupational exposure bands of 3A and 3B by SafeBridge.

“Our investments in suite upgrades and capacity expansion in Longmont have transformed the site into a worldclass API manufacturing facility,” said Ken Domagalski, general manager of the Avista Pharma Longmont facility. “Our team of experienced scientists prides itself in finding the most efficient path to success for our clients, further demonstrating our facility as a CMC center of excellence.”

The API facility expansion is one of several major investments at the Longmont site during 2017. Avista Pharma is also in the process of expanding its drug product manufacturing capacity and analytical capacity, as well as adding walk-in stability storage chambers into the additional 20,000-square-foot expansion announced last year.

(Source: Avista Pharma Solutions, Inc.)

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
Prolific Machines logo.
Prolific Machines enters FDA program to enhance therapeutics manufacturing platform
Genentech roche
Roche, Genentech to build $700M drug manufacturing plant in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE